Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations

Trial Profile

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2019

At a glance

  • Drugs Cetrelimab (Primary) ; Erdafitinib (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NORSE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Dec 2018 Planned End Date changed from 22 Jun 2023 to 30 Nov 2022.
    • 14 Sep 2018 Planned End Date changed from 15 Oct 2020 to 22 Jun 2023.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top